In conclusion, treatment of critical COVID-19 patients with low dose DXM resulted in a reduction of the inflammatory and lymphoid immune response but had little impact on the myeloid immune response, and no effect on endothelial activation, NETosis formation, and COVID-19-induced coagulopathy with persistent elevated levels of circulating TF. Here, TF is linked to COVID-19.